• Home
  • Search Results

Search Results

432 studies match your search
Open

CAR-T Cells in the Treatment of Patients with B Cell Malignancies

Have you been diagnosed with a B cell disease that has returned after your previous treatment or is not responding to your current treatment? If so, you might be able to take part in a study to see if a new treatment is safe and can help treat people with B-cell diseases.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Coming Soon

Financial Experiences of Young Adults with Cervical Cancer

We are conducting a study to ask young adults with cervical cancer what information they think would be useful to include in a skill-building program to help navigate the financial aspects of cancer treatment. We will interview young adults with cervical cancer to learn about what is important to them and then ask for feedback on versions of the program as we develop it.

Age & Gender
  • 18 years ~ 39 years
  • Female, Gender Inclusive
Study Interest
  • Cancer (Cervical)
  • Mental and Emotional Health
  • Opinions and Perceptions
  • Women's Health
Visit Location
100% Remote (online, phone, text)
Open

Lung Map Sub-Study S1900G

Do you have Non-Small Cell Lung Cancer? Have you previously been treated with Osimertinib? If so, you may be eligible for a trial comparing osimertinib in combination with other medications to treat your lung cancer. Please reach out if you're interested!

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lung)
Open

A012103-CIRB: OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY

Have you been diagnosed with early stage triple negative breast cancer? We are asking you to take part in this research study because you have been diagnosed with triple-negative breast cancer (TNBC) and have recently completed preoperative chemotherapy in combination with pembrolizumab, followed by breast surgery. The chemotherapy plus pembrolizumab produced a pathologic complete response (pCR), meaning that no remaining cancer was found during your breast surgery.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Open

Breast Cancer Tumor Tissue Study

Have you been diagnosed with breast cancer? If so, you may be able to take part in a research study for the collection of tumor specimens and genomic DNA from patients with early or metastatic breast cancer.

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Breast)
Not currently enrolling

Feedback needed to increase risk awareness of Prostate Cancer among Black/African American males

Community-based interventions outside of North Carolina increase prostate cancer risk awareness and education among African Americans. Help us design an ideal intervention for/with communities in North Carolina. Your feedback and insight are instrumental in raising awareness and ultimately saving the lives of Black/African American men in North Carolina.

Age & Gender
  • 18 years ~ 40 years
  • Male
Study Interest
  • Cancer (Prostate)
  • Healthy Volunteer or General Population
  • Minority Health
  • Men's Health
Visit Location
100% Remote (online, phone, text)
Open

Phase 2 study for Patients with Advanced Melanoma

Do you have stages 3-5 advance melanoma that is unresectable? Are you currently receiving standard therapy for your cancer? You may be able to participate in a research study to help us find out if your length of treatment could be reduced.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Melanoma)
Open

Testing Nivolumab and Ipilimumab Immunotherapy With or Without Cabozantinib

Do you Patients with have Advanced Nasopharyngeal Carcinoma that has Progressed After Platinum Treatment and Immunotherapy? If so, you may be able to participate in a research study to find out if progression-free survival of the triplet combination (CaboNivoIpi) is more favorable than the doublet (NivoIpi).

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Head and Neck)
Not currently enrolling

A Phase II Study of CyBorD Plus Daratumumab for Patients with MGRS

The purpose of this study is to find out whether a combination of drugs is a safe treatment for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. The combination of drugs in this study is cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC. In addition, we will find out whether the study drug combination is an effective treatment for these conditions.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Multiple Myeloma)
  • Kidneys and Liver
Open

Hormone Positive Breast Cancer Study for Premenopausal Patients

Are you a premenopausal woman with hormone-positive breast cancer? If so, you may be able to participate in a study to learn if adding chemotherapy to the usual treatment improves survival and decreases the chances of cancer coming back.

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Breast)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research